
feb pm et
summari lead biotech compani major treatment anemia neutropenia
rheumatoid psoriat arthriti psoriasi cancer osteoporosi
price-to-earnings oper ep
risk assess reflect particip
highli competit regul market subject
chang govern reimburs polici
drug safeti oversight see risk mitig
diversifi product roster gener robust
cash flow support share repurchas cash dividend
new asset acquisit
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
star recommend
recent chang hold
buy target price
recent chang
highlight section stock report
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
see
et cfra lower
buy lower
target line
peer ep estim
set ep
vs view sale
fell matur product sale continu
fall enbrel sale fell lower demand
sell price neulasta sale flat
newer drug solid gain repatha
prolia kyproli rose
also see repatha sale benefit
cardiovascular data ad prescrib
inform still see sale fall
soft matur product /jeffrey loo cfa
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview among world largest biotech compani market five world
compani announc fda grant approv repatha adjunct diet
maxim toler statin therapi treatment adult heterozyg famili
hypercholesterolemia clinic atherosclerot cardiovascular diseas requir addit lower
ldl-c adjunct diet ldl-lower therapi treatment patient
homozyg famili hypercholesterolemia requir addit lower ldl-c
compani announc european commiss ec grant market author repatha
treatment high cholesterol adjunct diet
major concentr compani sale market forc base europ
addit compani market product part latin america middl east asia
 compani sell primarili pharmaceut wholesal distributor turn sell
product health care provid compani also market certain product directli consum
direct-to-consum print televis advertis well multi-channel market
outsid compani sell princip health care provid and/or pharmaceut wholesal
distributor depend distribut practic countri
compani product sale three major wholesal cardin
account approxim total revenu year end decemb
enbrel etanercept compani market enbrel primarili medic use primarili
treatment adult patient moder sever activ rheumatoid arthriti chronic
moderate-to-sever plaqu psoriasi patient candid system therapi phototherapi
activ psoriat arthriti right market sell enbrel outsid canada
neulasta pegfilgrastim compani market neulasta pegyl protein base filgrastim
molecul primarili europ neulasta use primarili help reduc chanc infect
due low white blood cell count peopl certain type cancer non-myeloid receiv
anti-canc medicin chemotherapi caus fever low blood cell count
aranesp darbepoetin alfa compani market aranesp primarili europ aranesp
indic treatment anemia caus chronic kidney diseas ckd patient dialysi
patient dialysi aranesp also indic treatment anemia due concomit
myelosuppress chemotherapi patient non-myeloid malign chemotherapi
would use least two month start aranesp
epogen epoetin alfa compani market epogen dialysi patient compani
market epogen treat lower-than-norm number red blood cell anemia caus ckd
patient dialysi lessen need red blood cell transfus major compani sale
two dialysi provid
sensipar/mimpara cinacalcet compani market cinacalcet sensipar primarili
mimpara primarili europ use primarili treatment secondari hyperparathyroid
adult patient ckd dialysi
xgeva denosumab compani market xgeva primarili europ xgeva use primarili
prevent skeletal-rel event sre patholog fractur radiat bone spinal cord
compress surgeri bone patient bone metastas solid tumor
prolia denosumab compani market prolia primarili europ contain
activ ingredi xgeva approv differ indic patient popul dose
frequenc administr use primarili treatment postmenopaus women
osteoporosi high risk fractur
oper
chief offic
vice presid
chairman chief
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
biosimilar drug approv set
exclus brand drug maker see
biosimilar advanc modest rate
next sever year march fda
approv novarti filgrastim biosimilar
sandoz began sell biosimilar
name zarxio septemb april
fda approv inflectra manufactur
celltrion co-market inflectra
biosimilar johnson johnson
remicad began ship inflectra
risk novemb discount
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug note prescript
benefit manag health insur
exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 year date
septemb biotech index
rose vs rise
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci
anticip limit sale growth
mainli due forecast
sale declin
robust growth period
compound annual growth rate think
sale growth somewhat limit
heighten focu high drug price
encourag view strong period
report late-stag clinic
result accommod fda
approv howev fda approv
new drug significantli
robust new drug approv
sinc record approv
think mani newly-approv drug
signific commerci prospect repres
major advanc therapi diseas
cystic fibrosi hepat multipl
sclerosi cancer expect wider
adopt biomark research
genetic-target clinic studi help
late fda introduc
speed develop promis program
expect favor merger acquisit
climat larg pharmaceut firm move
off-set lost revenu expir drug patent
larg biotech bolster drug pipelin
scale acquisit
industri bellweth becam first
biotech compani initi regular dividend
began dividend payment
establish fda author govern
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
commiss ms step compani chief account offic
longer serv compani princip account offic
connect chang david melin compani execut vice
presid chief offic addit role act
compani princip account offic time new chief account
offic appoint
held may announc retir director frank
 biondi jr judith pelham
et cfra keep buy opinion share inc
keep target slightli peer
ep estim near high-end rang
ep vs ahead estim sale
fell enbrel sale fell amid increas competit repatha sale
remain soft agmn negoti payer improv access drug
keep sale guidanc rais low end ep
guidanc concern agmn matur drug
portfolio view new drug pipelin posit /jeffrey loo cfa
et capit iq reiter buy opinion share
inc releas posit data
patient fourier trial repatha result show repatha cut overal major
advers cardiovascular event includ heart attack stroke
coronari revascular observ effect
cardiovascular mortal view result posit uncertain
result enough convinc insur reimburs repatha hefti
price effort remov barrier access
offer refund repatha cost patient stroke heart attack
announc appoint charl holley jr board
director holley serv member audit committe
corpor respons complianc committe board follow
appoint holley board compris director
independ holley former execut vice presid chief
financi offic store inc serv
execut vice presid jan jan
analyst research note compani news
et cfra lower opinion share hold buy
lower target line
peer ep estim set
ep vs view sale fell matur
product sale continu fall enbrel sale fell lower demand
sell price neulasta sale flat newer drug solid gain
repatha prolia kyproli rose also see repatha
sale benefit cardiovascular data ad prescrib inform
still see sale fall soft matur product /jeffrey loo
et cfra keep buy opinion share inc
keep target price slightli peer
forward ep estim ep vs
estim rais ep estim
sale fell line forecast newer product
includ prolia blincyto kyproli
matur product line continu declin howev oper margin
improv basi point improv cost control manufactur
effici aid expir enbrel residu royalti payment
amgen inc appoint wanda austin director compani effect
upon decemb board committe meet dr austin retir
presid chief execut offic aerospac corpor
serv retir dr austin serv
member board audit committe corpor respons
complianc committe follow appoint dr austin board
compris director independ upon effect date
appoint board dr austin entitl standard
director compens thu receiv pro-rat portion annual
retain decemb receiv
committe meet attend person telephon
attend dr austin receiv pro-rat portion
annual grant fulli vest restrict stock unit date two
busi day releas compani fourth quarter
earn accord compani polici dr austin also
entitl reimburs expens incur connect
attend board committe meet confer senior
zymework inc announc appoint dr natali sack board director
previous vice presid clinic develop onyx
acquir play key role
develop approv kyproli fda-approv therapi
treatment relaps refractori multipl myeloma busi
et cfra reiter buy opinion share inc
rais target slightli peer
forward ep estim ep vs
ahead estim rais ep estim
sale rose new product sale includ prolia kyproli
partial off-set declin older drug repatha sale increas
still forecast see gradual uptak
narrow sale guidanc
increas ep estim /jeffrey
may compani appoint annett vice presid
financ chief account offic amgen inc serv vice
presid chief audit execut effect upon file
compani second quarter secur exchang
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
